NSCLC patients treated with immune checkpoint inhibitors display durable responses in a subset of patients, but it is currently difficult to predict which patients will benefit from this expensive treatment using current tumour tissue biomarkers, such as the protein expression levels of programmed death ligand 1 (PD-L1). The gene discussed is CD274; the disease is neoplasm.